Purity >98%. Nuclear retinoic acid receptors (RARs) are transcriptional regulators with roles in cell proliferation and differentiation. BMS 453 is a synthetic retinoid that acts as an agonist of RARBeta and an antagonist of RARAlpha and RARGamma. It has been shown to inhibit the proliferation of normal breast cells via the induction of TGF-Beta activity, causing G1 arrest. BMS 453 binding to RARAlpha and RARGamma can induce a transrepression of phorbol ester-induced AP-1 activity (IC50 s = ~0.1 nM in HeLa and MCSF-7 cells), which also correlates with reduced cell proliferation. BM 453 has been used to trigger the differentiation of mouse embryonic stem cells (mES) in a study of RARBeta-induced mES cell adipogenesis.